ARCHIVES

ODAC Recommends Approval Of Paxen; Will IVAX Break Into $1 Billion Market

This article is from The Cancer Letter archive.

Vol. 23 No. 37 | September 26, 1997

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 7 Issue 4, Assembly Edition 1993

September 13, 1993

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

May 4, 2001

Some Long-Term Survivors At Higher Risk Of Stroke

November 24, 2006

NCI Extramural Programs: NCAB Approves Guidelines for Cancer Center Grants

March 7, 1997

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

Abstracts From AACR Annual Meeting

May 21, 1976